Clinical settingPatients with cancer of unknown primary
Participants and Country57 tumour samples. Frozen and FFPE tissue. USA
Study designDiagnostic test validation
Target conditionIdentification of primary tumour tissue of origin. Reference standard was not reported.
Tests92 gene RT-PCR (Theros CancerType ID).
Follow upNot applicable
Commercially available assayTheros CancerType ID
Bioinformatic strategySee primary Theros CancerType ID reference
Validation methodSee primary Theros CancerType ID reference
NotesAbstract only. Unclear how CUP primary tumour was diagnosed.

From: Guideline chapter 2, Diagnosis

Cover of Diagnosis and Management of Metastatic Malignant Disease of Unknown Primary Origin
Diagnosis and Management of Metastatic Malignant Disease of Unknown Primary Origin.
NICE Clinical Guidelines, No. 104.
National Collaborating Centre for Cancer (UK).
Copyright © 2010, National Collaborating Centre for Cancer.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licenses issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.